Clinical Trial: Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional
Official Title:
Brief Summary: Compare the incidence of severe clinical exacerbations in the treatment of ABPA, between a strategy with a maintenance treatment and a conventional strategy without antifungal maintenance therapy.
Detailed Summary:
Sponsor: Poitiers University Hospital
Current Primary Outcome: occurrence of first severe clinical exacerbation [ Time Frame: within 24 months following the attack treatment, ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Poitiers University Hospital
Dates:
Date Received: October 22, 2014
Date Started: November 2014
Date Completion:
Last Updated: January 11, 2017
Last Verified: January 2017